AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
1.33
-0.08 (-5.67%)
After Hours: 1.35 +0.02 (1.50%)
Apr 23, 5:56PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.33 - 1.42
52 week 1.27 - 8.40
Open 1.42
Vol / Avg. 394,487.00/745,694.00
Mkt cap 68.89M
P/E     -
Div/yield     -
EPS -2.11
Shares 51.79M
Beta 0.84
Inst. own 68%
Apr 28, 2014
Q1 2014 AVEO Oncology Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 AVEO Oncology Earnings Conference Call - Webcast
Mar 13, 2014
Q4 2013 AVEO Oncology Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -5178.02% -8277.57%
Operating margin -4974.92% -8035.89%
EBITD margin - -7121.96%
Return on average assets -43.36% -60.50%
Return on average equity -86.14% -113.33%
Employees 219 -
CDP Score - -

Address

650 E. KENDALL STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2995000 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVEO Pharmaceuticals, Inc. is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies. The Company�s Human Response Platform, a method of building preclinical models of human cancer, provides the Company with insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. Tivozanib is the Company�s lead product candidate, which the Company partnered with Astellas Pharma Inc. (Astellas) during the year ended December 31, 2011. Tivozanib is an inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. In January 2012, the Company announced data from its global, phase III clinical trial of tivozanib, a therapy for first-line treatment in renal cell carcinoma (RCC), which the Company refers to as the TIVO-1 study.

Officers and directors

Henri A. Termeer Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Tuan Ha-Ngoc President, Chief Executive Officer, Principal Financial Officer, Director
Age: 61
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
Mary Ellen Jones Senior Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Jeno Gyuris Ph.D. Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Michael P. Bailey Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
William J. Slichenmyer M.D Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 62
Bio & Compensation  - Reuters
Robert S. Epstein M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters